Pierre Massion
Faculty Member
Last active: 1/11/2018

  1. Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Boutaud O, Sosa IR, Amin T, Oram D, Adler D, Hwang HS, Crews BC, Milne G, Harris BK, Hoeksema M, Knollmann BC, Lammers PE, Marnett LJ, Massion PP, Oates JA (2016) Cancer Prev Res (Phila) 9(11): 855-865
    › Primary publication · 27554763 (PubMed) · PMC5093073 (PubMed Central)
  2. Fluorescence-based measurement of cystine uptake through xCT shows requirement for ROS detoxification in activated lymphocytes. Siska PJ, Kim B, Ji X, Hoeksema MD, Massion PP, Beckermann KE, Wu J, Chi JT, Hong J, Rathmell JC (2016) J Immunol Methods : 51-58
    › Primary publication · 27594594 (PubMed) · PMC5065394 (PubMed Central)
  3. Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. Schabath MB, Massion PP, Thompson ZJ, Eschrich SA, Balagurunathan Y, Goldof D, Aberle DR, Gillies RJ (2016) PLoS One 11(8): e0159880
    › Primary publication · 27509046 (PubMed) · PMC4980050 (PubMed Central)
  4. Biomarkers of risk to develop lung cancer in the new screening era. Atwater T, Massion PP (2016) Ann Transl Med 4(8): 158
    › Primary publication · 27195276 (PubMed) · PMC4860477 (PubMed Central)
  5. Accumulation of isolevuglandin-modified protein in normal and fibrotic lung. Mont S, Davies SS, Roberts Second LJ, Mernaugh RL, McDonald WH, Segal BH, Zackert W, Kropski JA, Blackwell TS, Sekhar KR, Galligan JJ, Massion PP, Marnett LJ, Travis EL, Freeman ML (2016) Sci Rep : 24919
    › Primary publication · 27118599 (PubMed) · PMC4847119 (PubMed Central)
  6. Validation of a multiprotein plasma classifier to identify benign lung nodules. Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, Walker MG, Shi J, Kearney P, Fang KC, Massion PP (2015) J Thorac Oncol 10(4): 629-37
    › Primary publication · 25590604 (PubMed) · PMC4382127 (PubMed Central)
  7. The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers. Qian J, Hassanein M, Hoeksema MD, Harris BK, Zou Y, Chen H, Lu P, Eisenberg R, Wang J, Espinosa A, Ji X, Harris FT, Rahman SM, Massion PP (2015) Proc Natl Acad Sci U S A 112(11): 3469-74
    › Primary publication · 25733852 (PubMed) · PMC4371932 (PubMed Central)
  8. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X, Harris FT, Harris BK, Boyd KL, Chen H, Eisenberg R, Massion PP (2015) Int J Cancer 137(7): 1587-97
    › Primary publication · 25821004 (PubMed) · PMC4640891 (PubMed Central)
  9. Secretory IgA from submucosal glands does not compensate for its airway surface deficiency in chronic obstructive pulmonary disease. Du RH, Richmond BW, Blackwell TS, Cates JM, Massion PP, Ware LB, Lee JW, Kononov AV, Lawson WE, Blackwell TS, Polosukhin VV (2015) Virchows Arch 467(6): 657-665
    › Primary publication · 26432569 (PubMed) · PMC5081073 (PubMed Central)
  10. Reproducibility of Volumetric Computed Tomography of Stable Small Pulmonary Nodules with Implications on Estimated Growth Rate and Optimal Scan Interval. Smith GT, Rahman AR, Li M, Moore B, Gietema H, Veronesi G, Massion PP, Walker RC (2015) PLoS One 10(9): e0138144
    › Primary publication · 26379272 (PubMed) · PMC4575025 (PubMed Central)